Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Palyca

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet needPaul Palyca, Vadim P Koshenkov, Janice M Mehnert
The Prostate|October 17, 2023
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancerAaron P Mitchell, Sonia Persaud, Paul Palyca, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
JCO Oncology Practice|November 3, 2025
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate CancerAaron P Mitchell, Andrew Salner, Paul Palyca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet needPaul Palyca, Vadim P Koshenkov, Janice M Mehnert
The Prostate|October 17, 2023
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancerAaron P Mitchell, Sonia Persaud, Paul Palyca, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
JCO Oncology Practice|November 3, 2025
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate CancerAaron P Mitchell, Andrew Salner, Paul Palyca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Pageof 1